Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized…
| Price | $1.36 |
|---|---|
| Market cap | $104.82M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 0.76-3.31 |
| Beta | 1.46 |
Explore CRDF's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.